IDXX vs ZBH
Idexx Laboratories vs Zimmer Biomet — AI-powered side-by-side comparison
IDXX
Idexx Laboratories
69
Buy
VS
| Metric | IDXX | ZBH |
|---|
| AI Score |
69
|
70
|
| Price |
$586.77
|
$96.61
|
| P/E Ratio |
41.20×
|
23.38×
|
| ROE |
66.0%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
62.4%
|
69.9%
|
| Debt / Equity |
0.60×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
65.3
|
58.9
|
| Beta |
1.549
|
0.468
|
| Expected Upside |
+12.3%
|
+1.2%
|
AI Committee View
Current Innellis committee reasoning for IDXX versus ZBH.
ZBH leads by 1 points.
ZBH scores 70/100 (Buy) versus IDXX at 69/100 (Buy).
IDXX Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Stochastic RSI (90.3) confirms overbought conditions.
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
ZBH Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Risk/reward is unfavorable: 11.2% downside vs 1.2% upside.